Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IFCT-0301: Gefitinib vs Gemcitabine vs Docetaxel in PS 2-3 NSCLC
NCT00198393Phase 2Completed
- Sponsor
- IFCT
- Start
- Nov 2004
- Primary completion
- Jun 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of gefitinib, gemcitabine and docetaxel in non-small cell lung cancer (NSCLC) (3 arms), sponsored by IFCT. Primary endpoint: Progression-Free Survival. Started Nov 2004; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00198393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00198393.